| Artículo | 2024 |
Cancer nano-immunotherapy: the novel and promising weapon to fight cancer
|
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| Artículo | 2024 |
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma
|
FRONTIERS IN IMMUNOLOGY |
| Artículo | 2024 |
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
|
ANNALS OF ONCOLOGY |
| Artículo | 2024 |
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2024 |
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
|
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| Revisión | 2024 |
Technical considerations for isolated limb perfusion: A consensus paper
|
EJSO |
| Revisión | 2023 |
A genetic profiling guideline to support diagnosis and clinical management of lymphomas
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Editorial | 2023 |
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
|
CLINICAL CANCER RESEARCH |
| Resumen congreso | 2023 |
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Tumor Location in the Phase 3 KEYNOTE-716 Study
|
Annals of Surgical Oncology |
| Artículo | 2023 |
Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2023 |
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
|
LANCET ONCOLOGY |
| Artículo | 2023 |
Circulating myeloid-derived suppressor cells may be a useful biomarker in the follow-up of unvaccinated COVID-19 patients after hospitalization
|
FRONTIERS IN IMMUNOLOGY |
| Revisión | 2023 |
Defining the emergence of new immunotherapy approaches in breast cancer: role of myeloid-derived suppressor cells
|
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| Revisión | 2023 |
Dendritic cells: the yin and yang in disease progression
|
FRONTIERS IN IMMUNOLOGY |
| Capítulo | 2023 |
Knowing the myeloid-derived suppressor cells: another enemy of sarcomas patients
|
Myeloid-derived suppressor cells |
| Artículo | 2023 |
Matrix Metalloproteinase-9 Expression Is Associated with the Absence of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
|
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| Revisión | 2023 |
Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
|
FRONTIERS IN ONCOLOGY |
| Resumen congreso | 2023 |
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2023 |
Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination.
|
JOURNAL OF CLINICAL ONCOLOGY |
| Resumen congreso | 2023 |
Primary results of SOLTI-1503 PROMETEO phase 2 trial of Combination of Talimogene Laherparepvec (T-VEC) with Atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy
|
CANCER RESEARCH |
| Artículo | 2023 |
Prognostic implications of the residual tumor microenvironment after neoadjuvant chemotherapy in triple-negative breast cancer patients without pathological complete response
|
CANCERS |
| Artículo | 2023 |
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
|
Therapeutic Advances in Medical Oncology |
| Artículo | 2023 |
Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report
|
FRONTIERS IN IMMUNOLOGY |
| Resumen congreso | 2023 |
Unicentric experience with icdk4/6 in metastatic breast cancer
|
CANCER RESEARCH |
| Artículo | 2023 |
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
|
Breast Cancer Research |
| Artículo | 2022 |
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
|
EUROPEAN JOURNAL OF CANCER |
| Artículo | 2022 |
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: health-related quality of life from the randomized phase 3 KEYNOTE-716 study
|
EUROPEAN JOURNAL OF CANCER |
| Artículo | 2022 |
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
|
LANCET ONCOLOGY |
| Artículo | 2022 |
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
|
CANCERS |
| Artículo | 2022 |
Ewing sarcoma meets epigenetics, immunology and nanomedicine: moving forward into novel therapeutic strategies.
|
CANCERS |
| Artículo | 2022 |
Genes involved in immune reinduction may constitute biomarkers of response for metastatic melanoma patients treated with targeted therapy
|
Biomedicines |
| Resumen congreso | 2022 |
IL17-producing γδ T cells promote resistance to CDK4/6 inhibitors in HR+HER2- breast cancer
|
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| Artículo | 2022 |
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
|
CLINICAL CANCER RESEARCH |
| Artículo | 2022 |
Low levels of granulocytic myeloid-derived suppressor cells may be a good marker of survival in the follow-up of patients with severe COVID-19
|
FRONTIERS IN IMMUNOLOGY |
| Artículo | 2022 |
Obesity and risk for lymphoma: possible role of leptin.
|
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
| Artículo | 2022 |
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
|
BMC CANCER |
| Artículo | 2022 |
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
|
LANCET |
| Artículo | 2022 |
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial
|
LANCET ONCOLOGY |
| Artículo | 2022 |
Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases
|
FRONTIERS IN IMMUNOLOGY |
| Artículo | 2022 |
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma
|
LEUKEMIA & LYMPHOMA |
| Artículo | 2022 |
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)
|
EUROPEAN JOURNAL OF CANCER |
| Artículo | 2022 |
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
|
Breast |
| Revisión | 2022 |
The complexity of cancer immunotherapy illustrated through skin tumors
|
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS |
| Revisión | 2022 |
The effects of dendritic cell-based vaccines in the tumor microenvironment: impact on myeloid-derived suppressor cells
|
FRONTIERS IN IMMUNOLOGY |
| Revisión | 2022 |
Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
|
CANCERS |
| Artículo | 2021 |
5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study
|
CLINICAL CANCER RESEARCH |
| Artículo | 2021 |
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
|
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| Corrección | 2021 |
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
|
Scientific reports |
| Artículo | 2021 |
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
|
Scientific reports |
| Artículo | 2021 |
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
|
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| Corrección | 2021 |
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]
|
ANNALS OF ONCOLOGY |
| Artículo | 2021 |
Desarrollo de un protocolo de monitorización de fuga en perfusión de miembro aislado con gammacámara portátil
|
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR |
| Revisión | 2021 |
Immunometabolism modulation in therapy
|
Biomedicines |
| Artículo | 2021 |
Increased blood monocytic myeloid derived suppressor cells but low regulatory T lymphocytes in patients with mild COVID-19
|
VIRAL IMMUNOLOGY |
| Artículo | 2021 |
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
|
NATURE COMMUNICATIONS |
| Revisión | 2021 |
Leptin, both bad and good actor in cancer
|
BIOMOLECULES |
| Artículo | 2021 |
Lower survival and increased circulating suppressor cells in patients with relapsed/refractory diffuse large B-cell lymphoma with deficit of vitamin D levels using R-GDP plus lenalidomide (R2-GDP): Results from the R2-GDP-gotel trial
|
CANCERS |
| Revisión | 2021 |
Metabolic classification and intervention opportunities for tumor energy dysfunction
|
Metabolites |
| Artículo | 2021 |
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2021 |
Overall survival benefit with Tebentafusp in metastatic uveal melanoma
|
NEW ENGLAND JOURNAL OF MEDICINE |
| Artículo | 2021 |
Pembrolizumab plus gemcitabine in the subset of triple-negative advanced breast cancer patients in the geicam/2015-04 (Pangea-breast) study
|
CANCERS |
| Artículo | 2021 |
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
|
ANNALS OF ONCOLOGY |
| Artículo | 2021 |
Role of isolated limb perfusion in the era of targeted therapies and immunotherapy in melanoma. A systematic review of the literature
|
CANCERS |
| Artículo | 2021 |
SEOM clinical guideline for the management of cutaneous melanoma (2020)
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2020 |
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
|
LANCET ONCOLOGY |
| Revisión | 2020 |
An integral view of cancer (III). Evaluation of new biomarkers and treatment strategies
|
Revista Española de Patología |
| Resumen congreso | 2020 |
Evolution of cytotoxic and regulatory T cells in blood and in tissue after neoadjuvant treatment in breast carcinoma
|
ANNALS OF ONCOLOGY |
| Artículo | 2020 |
GEICAMGuidelines for the Management of Patients with Breast Cancer During theCOVID-19 Pandemic in Spain
|
ONCOLOGIST |
| Artículo | 2020 |
Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Revisión | 2020 |
Integrating the tumor microenvironment into cancer therapy
|
CANCERS |
| Artículo | 2020 |
Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report
|
MEDICINE |
| Artículo | 2020 |
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
|
NEW ENGLAND JOURNAL OF MEDICINE |
| Artículo | 2020 |
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2020 |
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer
|
FUTURE ONCOLOGY |
| Resumen congreso | 2020 |
SOLTI-1503 PROMETEO: Combination of talimogene laherparepvec (T-VEC) with atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy
|
CANCER RESEARCH |
| Revisión | 2019 |
2018 Consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary
|
Revista Española de Patología |
| Revisión | 2019 |
An integral view of cancer (I). The study, classification and reprogramming of the tumoral microclimate
|
Revista Española de Patología |
| Revisión | 2019 |
An integral view of cancer (II). Fields of investigation and emerging biomarkers
|
Revista Española de Patología |
| Resumen congreso | 2019 |
Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study
|
CANCER RESEARCH |
| Artículo | 2019 |
Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy
|
TRANSLATIONAL CANCER RESEARCH |
| Artículo | 2019 |
Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q"
|
HEALTH AND QUALITY OF LIFE OUTCOMES |
| Letter | 2019 |
Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group
|
LEUKEMIA & LYMPHOMA |
| Resumen congreso | 2019 |
Evolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy
|
ANNALS OF ONCOLOGY |
| Resumen congreso | 2019 |
Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort
|
JOURNAL OF CLINICAL ONCOLOGY |
| Resumen congreso | 2019 |
Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results
|
ANNALS OF ONCOLOGY |
| Resumen congreso | 2019 |
Myeloid derived-suppressor cells in healthy women and in advanced breast cancer patients
|
ANNALS OF ONCOLOGY |
| Revisión | 2019 |
New horizons in breast cancer: the promise of immunotherapy
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2019 |
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
|
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| Revisión | 2019 |
Obesity and Breast Cancer: Role of Leptin
|
FRONTIERS IN ONCOLOGY |
| Resumen congreso | 2019 |
Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB)
|
ANNALS OF ONCOLOGY |
| Editorial | 2019 |
Pneumonitis Related to Melanoma Immunotherapy
|
CLINICAL NUCLEAR MEDICINE |
| Artículo | 2019 |
Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma
|
ONCOLOGIST |
| Resumen congreso | 2019 |
Results from a phase II trial of pembrolizumab (P) plus gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study
|
ANNALS OF ONCOLOGY |
| Artículo | 2019 |
Reunión Anual de la SAPD: Abordaje de la toxicidad hepática tras el tratamiento con inhibidores de checkpoint en vida real
|
Revista Andaluza de Patología Digestiva |
| Resumen congreso | 2019 |
Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population
|
CANCER RESEARCH |
| Artículo | 2019 |
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Revisión | 2019 |
The tumour microenvironment as an integrated framework to understand cancer biology
|
CANCER LETTERS |
| Artículo | 2019 |
Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group
|
HEMATOLOGICAL ONCOLOGY |
| Artículo | 2019 |
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
|
PLOS ONE |
| Revisión | 2018 |
2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Resumen congreso | 2018 |
90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.
|
JOURNAL OF CLINICAL ONCOLOGY |
| Resumen congreso | 2018 |
A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative advanced breast cancer: GEICAM/2015-04 PANGEA-Breast
|
CANCER RESEARCH |
| Artículo | 2018 |
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
|
EUROPEAN JOURNAL OF CANCER |
| Resumen congreso | 2018 |
Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF(V600) mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2018 |
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma
|
BRITISH JOURNAL OF CANCER |
| Resumen congreso | 2018 |
Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22)
|
JOURNAL OF CLINICAL ONCOLOGY |
| Resumen congreso | 2018 |
Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma
|
BLOOD |
| Artículo | 2018 |
MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING
|
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE |
| Artículo | 2018 |
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
|
ANNALS OF ONCOLOGY |
| Resumen congreso | 2018 |
Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)
|
ANNALS OF ONCOLOGY |
| Artículo | 2018 |
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2018 |
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
|
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| Resumen congreso | 2018 |
Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast
|
ANNALS OF ONCOLOGY |
| Resumen congreso | 2018 |
Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study
|
CANCER RESEARCH |
| Artículo | 2018 |
SEOM clinical guideline for the management of malignant melanoma (2017)
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Resumen congreso | 2017 |
A phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER+/HER2-advanced or metastatic breast cancer (mBC) that has progressed during or after aromatase inhibitor (AI) therapy
|
JOURNAL OF CLINICAL ONCOLOGY |
| Revisión | 2017 |
Advances in the Immunobiological Therapies for Advanced Melanoma
|
ACTAS DERMO-SIFILIOGRAFICAS |
| Revisión | 2017 |
Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives
|
INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 331 |
| Artículo | 2017 |
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
|
JOURNAL OF TRANSLATIONAL MEDICINE |
| Resumen congreso | 2017 |
Follicular lymphoma: clinical and mollecular characteristics of histologic transformation
|
ANNALS OF ONCOLOGY |
| Resumen congreso | 2017 |
Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/2 Study Examining G100 Alone and in Combination with Pembrolizumab
|
BLOOD |
| Resumen congreso | 2017 |
Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2017 |
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
|
EUROPEAN JOURNAL OF CANCER |
| Resumen congreso | 2017 |
Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2017 |
Prognostic Value of Event-Free Survival at 12 and 24 Months and Long-Term Mortality for Non-Hodgkin Follicular Lymphoma Patients: A Study Report From the Spanish Lymphoma Oncology Group
|
CANCER |
| Artículo | 2016 |
Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel
|
BREAST CARE |
| Artículo | 2016 |
Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2016 |
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|
LANCET ONCOLOGY |
| Resumen congreso | 2016 |
Cost-Utility Analysis of Nivolumab Monotherapy for Metastatic Melanoma Treatment
|
VALUE IN HEALTH |
| Revisión | 2016 |
Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review
|
ENDOCRINE-RELATED CANCER |
| Resumen congreso | 2016 |
Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) plus vemurafenib (VEM) vs placebo (PBO) plus VEM in advanced BRAF-mutated melanoma patients (pts)
|
JOURNAL OF TRANSLATIONAL MEDICINE |
| Resumen congreso | 2016 |
GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases
|
ANNALS OF ONCOLOGY |
| Letter | 2016 |
Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib
|
FARMACIA HOSPITALARIA |
| Resumen congreso | 2016 |
Impact of the addition of rituximab in overall survival in first line chemotherapy in follicular lymphoma: a population-based study from the Spanish Lymphoma Oncology Group (GOTEL)
|
ANNALS OF ONCOLOGY |
| Resumen congreso | 2016 |
Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02
|
ANNALS OF ONCOLOGY |
| Artículo | 2016 |
Safety of vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: the Spanish experience
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2016 |
Sam68 Mediates the Activation of Insulin and Leptin Signalling in Breast Cancer Cells
|
PLOS ONE |
| Resumen congreso | 2016 |
Survival in young adults diagnosed with follicular lymphoma in a national registry from the Spanish Lymphoma Oncology Group
|
ANNALS OF ONCOLOGY |
| Artículo | 2016 |
Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study
|
MELANOMA RESEARCH |
| Resumen congreso | 2016 |
Two-year survival and safety update in patients (pts) with treatment-naive advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066
|
JOURNAL OF TRANSLATIONAL MEDICINE |
| Artículo | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Resumen congreso | 2015 |
Chemotherapy effectiveness in the treatment of non-medullary well-differentiated thyroid cancer: A systematic review
|
JOURNAL OF CLINICAL ONCOLOGY |
| Resumen congreso | 2015 |
Follicular lymphoma and clinical characteristics of histologic transformation
|
EUROPEAN JOURNAL OF CANCER |
| Artículo | 2015 |
Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study
|
PLOS ONE |
| Resumen congreso | 2015 |
Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) plus vemurafenib (VEM) in the phase 3 coBRIM study
|
EUROPEAN JOURNAL OF CANCER |
| Artículo | 2015 |
Inmunoterapia en cáncer de pulmón
|
Revisiones en Cáncer |
| Nota | 2015 |
Interview with Dr. L. de la Cruz Merino
|
Revisiones en Cáncer |
| Resumen congreso | 2015 |
Prospective study of the impact of the Prosigna (TM) assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study
|
CANCER RESEARCH |
| Artículo | 2015 |
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer
|
CURRENT MEDICAL RESEARCH AND OPINION |
| Resumen congreso | 2015 |
Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C)
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2015 |
SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2015 |
SEOM clinical guidelines for the treatment of Hodgkin's lymphoma
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2015 |
SEOM clinical guidelines in metastatic breast cancer 2015
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Resumen congreso | 2015 |
Survival analysis of follicular lymphoma in a national registry from the spanish oncology lymphoma group
|
EUROPEAN JOURNAL OF CANCER |
| Resumen congreso | 2015 |
Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2014 |
Avoidance of Cancer Cell Destruction by the Immune System
|
PATHOBIOLOGY OF HUMAN DISEASE: A DYNAMIC ENCYCLOPEDIA OF DISEASE MECHANISMS |
| Artículo | 2014 |
Clinical guideline SEOM: cancer of unknown primary site
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2014 |
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
|
NEW ENGLAND JOURNAL OF MEDICINE |
| Resumen congreso | 2014 |
Evaluation of changes on tumor-infiltrating lymphocytes and regulatory T-cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast cancer patients and relation with pathologic complete response
|
JOURNAL OF CLINICAL ONCOLOGY |
| Resumen congreso | 2014 |
Pathological complete response and changes related to t infiltrating lymphocytes and regulatory t cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast carcinoma
|
ANNALS OF ONCOLOGY |
| Revisión | 2014 |
Radiation for awakening the dormant immune system, a promising challenge to be explored
|
FRONTIERS IN IMMUNOLOGY |
| Revisión | 2014 |
Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma
|
THERAPEUTIC ADVANCES IN HEMATOLOGY |
| Resumen congreso | 2013 |
Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625
|
JOURNAL OF CLINICAL ONCOLOGY |
| Revisión | 2013 |
New Insights into the Role of the Immune Microenvironment in Breast Carcinoma
|
CLINICAL & DEVELOPMENTAL IMMUNOLOGY |
| Resumen congreso | 2013 |
Pathologic complete response and changes related to T-infiltrating lymphocytes and regulatory T cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast carcinoma
|
JOURNAL OF CLINICAL ONCOLOGY |
| Resumen congreso | 2013 |
Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC)
|
JOURNAL OF CLINICAL ONCOLOGY |
| Artículo | 2013 |
The prevalence and nature of cancer-related neuropathic pain in out-patient services in Spain
|
Open Pain Journal |
| Resumen congreso | 2012 |
Consolidaton treatment with Y90-ibritumomab tiuxetan after r-chop induction in high-risk patients with follicular lymphoma (fl) ( gotel -fl1lc): A multicentric, prospective study
|
ANNALS OF ONCOLOGY |
| Capítulo | 2012 |
Hodgkin's Lymphoma: From Tumor Microenvironment to Immunotherapeutic Approach - Body's Own Power Protection Challenges
|
Hodgkin's Lymphoma |
| Revisión | 2012 |
Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications
|
CLINICAL & DEVELOPMENTAL IMMUNOLOGY |
| Revisión | 2011 |
Immune Microenvironment in Colorectal Cancer: A New Hallmark to Change Old Paradigms
|
CLINICAL & DEVELOPMENTAL IMMUNOLOGY |
| Letter | 2011 |
Numb chin syndrome: A warning sign of aggressive B-cell malignancy
|
LEUKEMIA RESEARCH |
| Artículo | 2010 |
Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety
|
ONCOLOGIST |
| Artículo | 2010 |
Linfangitis carcinomatosa como presentación de un adenocarcinoma gástrico
|
Revista Andaluza de Patología Digestiva |
| Artículo | 2010 |
Primary intracranial malignant peripheral nerve sheath tumour responding to chemotherapy
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Revisión | 2010 |
Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes
|
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY |
| Artículo | 2009 |
Linfocitos infiltrantes de tumor. Implicación en el cáncer colorrectal
|
Revista Andaluza de Patología Digestiva |
| Artículo | 2009 |
Role of transforming growth factor β in cancer microenvironment
|
CLINICAL & TRANSLATIONAL ONCOLOGY |
| Artículo | 2008 |
Cancer and Immune Response: Old and New Evidence for Future Challenges
|
ONCOLOGIST |
| Artículo | 2008 |
Obstrucción intestinal maligna, sintomatología depresiva y solicitud de «eutanasia»
|
Medicina Paliativa |
| Resumen congreso | 2008 |
Phase II: Sequential scheme capecitabine-oxaliplatin followed by capecitabine-irinotecan ( oxxec-02) in first line metastatic colorectal cancer (mcrc). Study oxxec-02
|
ANNALS OF ONCOLOGY |
| Letter | 2007 |
Severe acute hepatitis in a patient treated with anastrozole
|
LANCET |
| Artículo | 2005 |
Cáncer de páncreas. Epidemiología, historia natual y estadificación
|
Revisiones en Cáncer |
| Artículo | 2005 |
Cáncer de vejiga: historia natural
|
Revisiones en Cáncer |
| Revisión | 2005 |
Pancreatic cancer. Epidemiology, natural history and staging
|
Revisiones en Cáncer |
| Resumen congreso | 2004 |
A multicenter sequential phase IV study of oxaliplatin (Oxa) and capecitabine (Cap) followed by irinotecan (Iri) and capecitabine in first line advanced colorectal cancer (ACC). Preliminary results
|
JOURNAL OF CLINICAL ONCOLOGY |
| Editorial | 2004 |
Beneficio clínico: beneficio ¿para quien?
|
Oncología |
| Artículo | 2003 |
Historial natural y estadificación del cáncer de cabeza y cuello
|
Revisiones en Cáncer |
| Revisión | 2003 |
Natural history and staging of head and neck cancer
|
Revisiones en Cáncer |
